Centre Hospitalier Universitaire de Lille

Running trials

• Not yet recruiting

  Risk-reducing Strategies, Including Fimbriectomy, in Women With a Germline Mutation Predisposing to Ovarian or Pelvic Cancer

  NCT06726330· Centre Oscar Lambret· Source

• Not yet recruiting

  Evaluation of an Intensified Systematic Screening for Congenital Hypothyroidism in Premature Newborns

  NCT07425028· University Hospital, Lille· Source

• Not yet recruiting

  A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination with Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants with First-Line Metastatic Pancreatic Ductal Adenocarcinoma

  2025-522563-15-00· Phase 2/3· AbbVie Deutschland GmbH & Co. KG· Source

• Not yet recruiting

  Safety and Efficacy of a STOPping Strategy Versus Classical Maintenance Dose of JAK Inhibitors in Deep Remission Patients With Ulcerative Colitis

  NCT07718529· Phase 4· Assistance Publique Hopitaux De Marseille· Source

• Not yet recruiting

  Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations

  NCT07738887· Phase 2· The Lymphoma Academic Research Organisation· Source

• Not yet recruiting

  Safety and Efficacy of VX-828/Deutivacaftor Combination Therapy With and Without Tezacaftor in Subjects With Cystic Fibrosis

  2025-523400-72-00· Phase 2· Vertex Pharmaceuticals Inc.· Source

• Not yet recruiting

  A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma

  NCT07612787· Phase 1/2· Centre Hospitalier Universitaire de Saint Etienne· Source

• Not yet recruiting

  FirST Lines of Biologics in pAtients With ulceRaTivE Colitis: a Randomised Controlled Trial

  NCT07576452· Phase 4· University Hospital, Clermont-Ferrand· Source

• Not yet recruiting

  Evaluation of the Effect of Time of Administration on the Activity on First Line of Pembrolizumab in Association With Carboplatin-pemetrexed in Metastatic Non-squamous Lung Cancer. A Randomised Multicenter Phase III Trial

  NCT07915037· Phase 3· Assistance Publique - Hôpitaux de Paris· Source

• Not yet recruiting

  A Phase 2 trial of AGMB-447 in participants with idiopathic pulmonary fibrosis

  2026-526404-71-00· Phase 2· Agomab Spain S.L.U.· Source

• Recruiting

  Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease

  NCT07781657· Phase 2· Hoffmann-La Roche· Source

• Not yet recruiting

  Efficacy of Upadacitinib Re-induction Therapy in Patients With Ulcerative Colitis Who Lost Response to 30 mg Maintenance Dose

  NCT07700446· Phase 4· Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives· Source

• Not yet recruiting

  A study in young people and adults to learn about the medicine ritlecitinib for treatment of patchy hair loss, known by the medical term as moderate alopecia areata

  2026-526355-62-00· Phase 3· Pfizer Inc.· Source

• Not yet recruiting

  A pivotal clinical study to investigate the safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis due to Metabolic dysfunction-associated steatohepatitis (MASH)

  2026-525755-82-00· Phase 3· Glaxosmithkline Research & Development Limited· Source

• Not yet recruiting

  A study to investigate safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis (stage F4 fibrosis) due to MASH (NEBULA-2)

  2026-525757-37-00· Phase 3· Glaxosmithkline Research & Development Limited· Source

• Not yet recruiting

  A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis

  NCT07873801· Phase 3· Almirall, S.A.· Source

• Not yet recruiting

  Impact of a Diagnosis or Lack of a Diagnosis of Endometriosis Via a Saliva Test on Pain Catastrophizing, Quality of Life, Symptoms of Anxiety and Depression, and Treatment Adherence

  NCT07915765· University Hospital, Lille· Source

• Not yet recruiting

  Evaluation of iNstroke Aspiration Catheters for Thrombectomy: a Multi-center Prospective Study

  NCT07376447· iVascular S.L.U.· Source

• Not yet recruiting

  Therapeutic Implications of CMR Low Native T1 in Non-treated Non-hypertrophic Females With Fabry Disease (FD)

  NCT07872852· University Hospital, Bordeaux· Source

• Not yet recruiting

  Efficacy and Safety Evaluation of iNstroke 5F Aspiration Catheter for Thrombectomy

  NCT07571954· iVascular S.L.U.· Source

• Not yet recruiting

  A trial to learn how well AZD0120 works and about its safety in adults with transplant eligible newly diagnosed multiple myeloma.

  2026-525367-40-00· Phase 3· AstraZeneca AB· Source

• Not yet recruiting

  A Multicenter, Phase 2/3, Dose Range Finding Study to Evaluate the Efficacy and Safety of Atumelnant in Adults with ACTH-Dependent Cushing’s Syndrome (ADCS) Including an Open-Label Extension for Long-Term Assessment. (EQUILIBRIUM-ADCS)

  2025-522648-42-01· Phase 2/3· Crinetics Pharmaceuticals Inc.· Source

• Not yet recruiting

  Bioavailability and Bioequivalence Study of Ziftomenib in Participants With Relapsed/Refractory AML or MDS

  NCT07929740· Phase 1· Kura Oncology, Inc.· Source

• Not yet recruiting

  A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity

  NCT07861100· Phase 3· Novo Nordisk A/S· Source

• Not yet recruiting

  Comparative Study of Two Vaccination Schedules for the Subunit Herpes Zoster Vaccine in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disease Patients Treated With Anti-CD20 Therapy: an Open-label Randomised Controlled Trial

  NCT07818356· Phase 4· University Hospital, Toulouse· Source

• Recruiting

  A Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia A

  NCT07830732· Phase 3· Novo Nordisk A/S· Source

• Not yet recruiting

  Impact of Fluorescence-Guided Resection and Chemoradiotherapy on the Systemic Immune Response in Glioblastoma: A Kinetic Analysis of Immune Biomarkers.

  NCT07568782· University Hospital, Lille· Source

• Not yet recruiting

  Evaluation of the Efficacy and Safety of Bimekizumab (BZK) or Adalimumab (ADA) in the Treatment of Anterior Chest Wall Pain Associated With Active Axial Spondyloarthritis Refractory to NSAIDs With Hypothesis of Superiority of Bimekizumab

  NCT07836283· Phase 3· University Hospital, Rouen· Source

• Recruiting

  A Phase IIa Trial Evaluating the Efficacy of anti-CD19 Chimeric Antigen Receptor Engineered T-Cells in Patients With Systemic Sclerosis (SSc) Resistant to Immunosuppressive Drugs. SCLEROCAR

  2024-519511-33-00· Phase 2· Centre Hospitalier Universitaire De Montpellier· Source

• Recruiting

  Phase 3 Study of Investigator Choice of Chemotherapy with or without Zoldonrasib as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma

  2025-524928-21-00· Phase 3· Revolution Medicines Inc.· Source

• Recruiting

  Switch to Ofatumumab and Level of Immunoglobulins

  NCT07625800· University Hospital, Lille· Source

• Not yet recruiting

  A clinical trial to learn more about the effects of DJI136 in people with extensive-stage small cell lung cancer

  2025-523276-23-00· Phase 1/2· Novartis Pharma AG· Source

• Recruiting

  Study of 18FET PET in functional pituitary adenomas with indeterminate MRI findings

  2025-523829-17-00· Phase 2· Centre Hospitalier Universitaire De Lille· Source

• Not yet recruiting

  Perioperative Yoga Therapy and Endometriosis Surgery

  NCT07765680· University Hospital, Lille· Source

• Not yet recruiting

  Evaluation of the Axomove Therapy Medical Device to Facilitate Adapted Physical Activity for Patients With Obesity

  NCT07903025· Axomove· Source

• Not yet recruiting

  Tenecteplase for the treatment of acute stroke in the late time window before inter-hospital transfer for thrombectomy: a randomized controlled trial

  2026-525280-40-00· Phase 3· Fondation A De Rothschild· Source

• Not yet recruiting

  Evaluate the superiority of Treatment with RAvulizumab vs plasma exchange during the first episode or a relapse In acute neuromyelitis optica (NMO) patients: a national, multicentric, randomised trial

  2026-526632-39-00· Phase 3· Les Hopitaux Universitaires De Strasbourg· Source

• Recruiting

  ODSSEY-SCD_Identification Of Markers to preDict the rISk of Sudden Cardiac Death in Moderated LVEF in ischEmic cardiomyopathY

  NCT07545512· University Hospital, Clermont-Ferrand· Source

• Recruiting

  A Phase 3 Study Comparing Ramantamig plus Daratumumab Versus DVRd or DRd in Participants With NDMM for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

  2026-526654-14-01· Phase 3· Janssen Cilag International· Source

• Recruiting

  A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis

  NCT07465289· Phase 3· UCB Biopharma SRL· Source

• Not yet recruiting

  Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease

  NCT07420439· Phase 2· Intergroupe Francophone de Cancerologie Thoracique· Source

• Recruiting

  A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

  NCT07623161· Phase 3· Takeda· Source

• Recruiting

  A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)

  2025-525009-18-00· Phase 3· Incyte Corp.· Source

• Recruiting

  A trial to learn how well AZD0120 works and how safe it is in people with relapsed or refractory multiple myeloma.

  2025-523285-25-00· Phase 3· AstraZeneca AB· Source

• Recruiting

  A Phase IIb Study to Evaluate AZD8965 in Participants with Idiopathic Pulmonary Fibrosis (IPF)

  2025-525016-41-00· Phase 2· AstraZeneca AB· Source

• Not yet recruiting

  Obinutuzumab for Systemic Lupus Erythematosus Pure Membranous Nephropathy: a Phase II Trial

  NCT07721363· Phase 2· Assistance Publique - Hôpitaux de Paris· Source

• Not yet recruiting

  Prospective evaluation of response to treatment by analysis of measurable residual disease in younger adult patients (18-60 years) with acute myeloid leukemia (AML). The Backbone InterGroup (BIG)-2 umbrella trial from the Acute Leukemia French Intergroup (ALFA, FILO) - BIG2

  2026-525759-96-00· Phase 4· Centre Hospitalier Universitaire De Toulouse· Source

• Not yet recruiting

  Short- and Mid-term Therapeutic, Prognostic, and Societal Impact of Implementing Intraoperative Assessment of Pulmonary Resection Quality for Lung Cancer

  NCT07828938· Fondation Hôpital Saint-Joseph· Source

• Not yet recruiting

  Evaluation of the Efficacy of Ischemic Preconditioning to Protect Against Acute Kidney Injury After Open Surgery for Juxtarenal Abdominal Aortic Aneurysm

  NCT07441564· University Hospital, Rouen· Source

• Not yet recruiting

  CUSHMAH - Benefit of steroidogenesis inhibitors in Mild Cushing syndrome (Mild Autonomous Cortisol Secretion): a randomized trial in patients with Primary Bilateral Macronodular Adrenocortical Hyperplasia

  2023-507010-27-00· Phase 3· Assistance Publique Hopitaux De Paris· Source

Showing 50 of 635.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer33 recruiting
• Childhood cancers24 recruiting
• Multiple myeloma22 recruiting
• Crohn's disease17 recruiting
• Acute myeloid leukaemia16 recruiting
• Colorectal cancer16 recruiting
• Gastric and oesophageal cancer15 recruiting
• Pancreatic cancer15 recruiting
• Stroke14 recruiting
• Multiple sclerosis12 recruiting
• Acute lymphoblastic leukaemia11 recruiting
• Epilepsy9 recruiting
• High blood pressure9 recruiting
• Liver and biliary tract cancer9 recruiting
• Melanoma9 recruiting
• Ulcerative colitis9 recruiting
• Coronary artery disease8 recruiting
• Systemic sclerosis (scleroderma)8 recruiting
• Fatty liver disease (MASLD/MASH)7 recruiting
• Haemophilia7 recruiting
• Myasthenia gravis7 recruiting
• Myelodysplastic syndromes7 recruiting
• Parkinson disease7 recruiting
• Chronic myeloid leukaemia6 recruiting
• Follicular lymphoma6 recruiting
• Heart failure6 recruiting
• Ovarian cancer6 recruiting
• Alzheimer disease5 recruiting
• Chronic lymphocytic leukaemia5 recruiting
• Idiopathic pulmonary fibrosis5 recruiting
• Neuroendocrine tumours5 recruiting
• Prostate cancer5 recruiting
• Aortic aneurysm4 recruiting
• Aortic stenosis4 recruiting
• Bladder cancer4 recruiting
• COPD4 recruiting
• Cushing's syndrome4 recruiting
• Diffuse large B-cell lymphoma4 recruiting
• Duchenne muscular dystrophy4 recruiting
• Lupus (SLE)4 recruiting
• Myeloproliferative neoplasms4 recruiting
• Type 1 diabetes4 recruiting
• ALS (motor neurone disease)3 recruiting
• ANCA-associated vasculitis3 recruiting
• Asthma3 recruiting
• Atopic dermatitis (eczema)3 recruiting
• Atrial fibrillation3 recruiting
• Dermatomyositis and polymyositis (myositis)3 recruiting
• Dilated cardiomyopathy3 recruiting
• Glioblastoma3 recruiting
• Head and neck cancer3 recruiting
• Hodgkin lymphoma3 recruiting
• Kidney cancer3 recruiting
• Mantle cell lymphoma3 recruiting
• Mesothelioma3 recruiting
• Neuromyelitis optica (NMOSD)3 recruiting
• Obesity3 recruiting
• Sickle cell disease3 recruiting
• Thyroid cancer3 recruiting
• Aplastic anaemia2 recruiting
• Barrett's oesophagus2 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)2 recruiting
• Congenital heart disease2 recruiting
• Cystic fibrosis2 recruiting
• Cytomegalovirus infection2 recruiting
• Depression2 recruiting
• Endometriosis2 recruiting
• Hidradenitis suppurativa2 recruiting
• Lewy body dementia2 recruiting
• Liver cirrhosis2 recruiting
• Osteoarthritis2 recruiting
• Primary biliary cholangitis2 recruiting
• Psoriasis2 recruiting
• Psoriatic arthritis2 recruiting
• Rheumatoid arthritis2 recruiting
• Sarcoidosis2 recruiting
• Schizophrenia2 recruiting
• Type 2 diabetes2 recruiting
• Alopecia areata1 recruiting
• Amyloidosis1 recruiting
• Ankylosing spondylitis1 recruiting
• Bronchiectasis1 recruiting
• Cervical cancer1 recruiting
• Chronic kidney disease1 recruiting
• Endometrial cancer1 recruiting
• Fabry disease1 recruiting
• Familial hypercholesterolaemia1 recruiting
• Hepatitis B1 recruiting
• Hepatitis C1 recruiting
• Huntington's disease1 recruiting
• Hypertrophic cardiomyopathy1 recruiting
• Hypothyroidism1 recruiting
• IgA nephropathy1 recruiting
• Insomnia1 recruiting
• Irritable bowel syndrome1 recruiting
• Myocarditis1 recruiting
• Neuroblastoma1 recruiting
• Obstructive sleep apnoea1 recruiting
• Osteoporosis1 recruiting
• Polycystic kidney disease1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Sarcoma1 recruiting
• Sjögren's disease1 recruiting
• Spinal muscular atrophy1 recruiting

Closed trials

• Withdrawn

  Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab

  NCT07039422· Phase 2· Novartis Pharmaceuticals· Source

• Completed

  Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults with Advanced Colorectal Cancer.

  2025-523984-39-00· Phase 2· Gilead Sciences Inc.· Source

• Completed

  A clinical trial to learn about the effects of VHB937 in people with Alzheimer's disease

  2024-516966-12-00· Phase 2· Novartis Pharma AG· Source

• Completed

  Study of the Effectiveness and Safety of Acasunlimab Alone or With Pembrolizumab in treating Advanced Melanoma of the Skin That Has Returned After or did not respond to Cancer Immunotherapy (ABBIL1TY MELANOMA-07)

  NCT06984328· Phase 2· Genmab A/S· Source

• Active, not recruiting

  A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma

  NCT07288203· Phase 2· Iovance Biotherapeutics, Inc.· Source

• Completed

  GSK4527226 Open-label Extension Study in Patients with Early Alzheimer's Disease.

  2025-521107-42-00· Phase 2· Glaxosmithkline Research & Development Limited· Source

• Completed

  Evaluation of long-term safety in parkinsonian patients with intracerebroventricular administration of A-dopamine (anaerobic dopamine) - (DIVE-Follow up)

  2025-522261-30-00· Phase 1/2· Centre Hospitalier Universitaire De Lille· Source

• Not yet recruiting

  Evaluation of Efficacy and Safety De-escalation Versus Standard Adjuvant Chemotherapy in Patients With Low Risk Localized Gastroesophageal Adenocarcinoma

  NCT06933966· Phase 2· Centre Leon Berard· Source

• Completed

  A multicentre, randomised, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of BP1.4979 in adult patients with essential tremor

  2024-517987-46-00· Phase 2· Bioprojet Pharma· Source

• Completed

  C4971006: A Study to Learn About the Effects of 2 Study Medicines (Maplirpacept [PF-07901801] and Glofitamab) When Given Together in People With Relapsed or Refractory Diffuse Large B Cell Lymphoma

  NCT05896163· Phase 1/2· Pfizer Inc.· Source

• Completed

  A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects with Primary Biliary Cholangitis

  2023-507771-22-01· Phase 3· Intercept Pharmaceuticals Inc.· Source

• Completed

  Characterization of Immune Response in Participants from a Posdinemab Study

  2024-514634-20-00· Phase 1· Janssen Cilag International· Source

• Active, not recruiting

  A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)

  NCT06593522· Phase 2· Amgen· Source

• Completed

  A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)

  NCT06637423· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Completed

  IFM 2020-01 (Isamyp) Efficacity assessment of isatuximab plus pomalidomide and dexamethasone in patients with AL amyloidosis who didn't reach at least a very good partial response with their previous treatment

  NCT05066607· Phase 2· Intergroupe Francophone Du Myelome· Source

• Completed

  Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures – SHINE

  NCT06425159· Phase 2/3· Biohaven Therapeutics Ltd.· Source

• Completed

  A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Abiprubart in Participants with Sjögren’s Disease

  2024-512986-15-00· Phase 2· Kiniksa Pharmaceuticals GmbH· Source

• Completed

  ALS Phase II Study of NX210c

  NCT06365216· Phase 2· Axoltis Pharma· Source

• Recruiting

  Efficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis

  2023-504358-36-00· Phase 3· Sanofi-Aventis Recherche & Developpement· Source

• Active, not recruiting

  To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications

  NCT06553027· Phase 3· Cerevance· Source

• Completed

  A study to test whether BI 1839100 improves cough in people with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis

  2023-510249-79-00· Phase 2· Boehringer Ingelheim International GmbH· Source

• Active, not recruiting

  Efficacy and Safety of Gemlapodect (NOE-105) in Adults and Adolescents With Tourette Syndrome

  NCT06315751· Phase 2· Noema Pharma AG· Source

• Completed

  A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT06335303· Phase 2· Boehringer Ingelheim· Source

• Active, not recruiting

  A Phase 1b Trial to Evaluate Safety of MB097 in Combination With Pembrolizumab in Melanoma Patients

  NCT06540391· Phase 1· Microbiotica Ltd· Source

• Completed

  Molecular Analysis of Thrombocytopenia and Cancer (MATAC): Investigating Antigenic Mimicry Between Platelets and Tumor Cells in Patients With Immune Thrombocytopenia (ITP) Associated With Cancer

  NCT06444477· University Hospital, Bordeaux· Source

• Completed

  Reperfusion with P2Y12 inhibitors in addition to mechanical thrombectomy for perfusion imaging selected acute stroke patients : a multicentric randomized controlled trial

  NCT04667078· Phase 4· Fondation A De Rothschild· Source

• Active, not recruiting

  NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

  NCT06379217· Phase 1· Novartis Pharmaceuticals· Source

• Completed

  A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF)

  2023-506185-31-00· Phase 2/3· Pliant Therapeutics Inc.· Source

• Active, not recruiting

  Lenvatinib Treatment in Waiting List of Liver Transplantation After TACE Failure in Patients With Hepatocellular Carcinoma

  NCT05901194· Phase 1/2· Assistance Publique - Hôpitaux de Paris· Source

• Completed

  A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.

  NCT06383403· Phase 3· Ipsen· Source

• Terminated

  To Evaluate Safety and Tolerability of the Fixed- Dose Combination of Obeticholic Acid and Bezafibrate

  NCT06488911· Phase 3· Intercept Pharmaceuticals· Source

• Completed

  Open-label Extension of Vericiguat in Pediatric Participants with Heart Failure due to Left Ventricular Systolic Dysfunction

  2023-506210-40-00· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Performance and Hearing-related Outcomes in Adults Implanted With the CI622D Dexamethasone-eluting Cochlear Implant Compared to Those Implanted With a Standard Cochlear Implant (CI622)

  NCT06424262· Cochlear· Source

• Completed

  Inflammatory Response in Children Suffering From Tethered Cord

  NCT07611058· University Hospital, Lille· Source

• Completed

  A Phase 1/2, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of IPH6501 in Patients with Relapsed and/or Refractory CD20-expressing Non-Hodgkin Lymphoma

  NCT06088654· Phase 1/2· Innate Pharma· Source

• Completed

  EFFICACY AND SAFETY OF GSK4527226 [AL101] IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE

  NCT06079190· Phase 2· Glaxosmithkline Research & Development Limited· Source

• Completed

  Glenzocimab in Anterior stroke with Large Ischemic Core eligible for Endovascular therapy

  2023-509615-92-00· Phase 2· Hopital Fondation Adolphe De Rothschild· Source

• Active, not recruiting

  A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

  NCT06346067· Phase 3· Erasca, Inc.· Source

• Completed

  A 52-week Clinical Trial to Study the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)

  NCT05813288· Phase 3· Areteia Therapeutics Inc.· Source

• Completed

  A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments

  NCT06323928· Phase 2· H. Lundbeck A/S· Source

• Recruiting

  A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

  NCT05509777· Phase 3· Eli Lilly and Company· Source

• Completed

  A clinical study of MK-6194 for the treatment of Systemic Lupus Erythematosus (SLE) (MK-6194-006)

  2023-505520-61-00· Phase 2/3· Merck Sharp & Dohme LLC· Source

• Completed

  A Phase 3 Study to Evaluate the Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants with Relapsed or Refractory Multiple Myeloma (RRMM)

  2023-509472-42-00· Phase 3· Celgene International II S.a.r.l.· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor

  NCT06241118· Phase 3· Sanofi· Source

• Withdrawn

  Home Monitoring of Adult Patients With SMA: a Pilot Multicenter Validation Study

  NCT05839145· Institut de Myologie, France· Source

• Completed

  A 96-Week, Prospective, Multicenter, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare Efficacy and Safety of Masitinib Dose Titration to 4.5 mg/kg/day versus Placebo in the Treatment of Patients with Primary Progressive or Secondary Progressive Multiple Sclerosis Without Relapse

  2024-516672-16-00· Phase 3· Ab Science· Source

• Completed

  A trial to find out if vidutolimod together with cemiplimab is safe and if it works in adult participants with advanced cancer or metastatic cancer

  NCT04916002· Phase 2· Regeneron Pharmaceuticals Inc.· Source

• Active, not recruiting

  A Study to Evaluate ABP 206 Compared with OPDIVO® (Nivolumab) in Subjects with Unresectable or Metastatic Melanoma

  2023-503288-40-00· Phase 3· Amgen Inc.· Source

• Terminated

  Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML

  NCT06268574· Phase 2· Ryvu Therapeutics SA· Source

• Completed

  A Multicenter, Open-Label Clinical Trial of RVU120 in Patients with Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia with or without NPM1 Mutation (RIVER-52)

  2023-505910-10-00· Phase 2· Ryvu Therapeutics S.A.· Source

Showing 50 of 238.

Conditions

Diseases this institution publishes on or runs trials for.

• Multiple myeloma51 works · 61 trials
• Multiple sclerosis43 works · 28 trials
• Systemic sclerosis (scleroderma)31 works · 15 trials
• Bladder cancer28 works · 10 trials
• Acute myeloid leukaemia28 works · 33 trials
• Crohn's disease27 works · 28 trials
• Pulmonary arterial hypertension18 works · 8 trials
• Hodgkin lymphoma16 works · 19 trials
• Frontotemporal dementia16 works · 1 trial
• Follicular lymphoma15 works · 19 trials
• Cystic fibrosis14 works · 5 trials
• Haemophilia11 works · 16 trials
• Cytomegalovirus infection10 works · 2 trials
• Mesothelioma9 works · 10 trials
• Myelodysplastic syndromes8 works · 17 trials
• Mantle cell lymphoma7 works · 10 trials
• Immune thrombocytopenia (ITP)6 works · 5 trials
• ANCA-associated vasculitis5 works · 5 trials
• Neuromyelitis optica (NMOSD)5 works · 4 trials
• Dermatomyositis and polymyositis (myositis)5 works · 6 trials
• Retinitis pigmentosa4 works · 0 trials
• Aplastic anaemia3 works · 2 trials